Clinical trial
Phase 3 Clinical Trial of Teriparatide in Japan
NCT00433160 · Eli Lilly and Company, Industry · Completed
Key facts
| NCT number | NCT00433160 |
|---|---|
| Title | Phase 3 Clinical Trial of Teriparatide in Japan |
| Official title | Efficacy and Safety of LY333334 in Japanese Patients With Osteoporosis |
| Lead sponsor | Eli Lilly and Company, Industry |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Osteoporosis |
| Intervention type | Drug |
| Interventions | Teriparatide, Placebo |
| Enrollment | 207 |
| Start date | Jan 1, 2007 |
| Primary completion | Sep 1, 2008 |
| Completion | Sep 1, 2009 |
| First posted | Feb 9, 2007 |
| Last update posted | Sep 21, 2010 |
| Countries | Japan |
At a glance
- 10–99 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: